[go: up one dir, main page]

WO2008144483A3 - Agents for treating disorders involving modulation of ryanodine receptors - Google Patents

Agents for treating disorders involving modulation of ryanodine receptors Download PDF

Info

Publication number
WO2008144483A3
WO2008144483A3 PCT/US2008/063857 US2008063857W WO2008144483A3 WO 2008144483 A3 WO2008144483 A3 WO 2008144483A3 US 2008063857 W US2008063857 W US 2008063857W WO 2008144483 A3 WO2008144483 A3 WO 2008144483A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
treating disorders
disorders involving
ryanodine receptors
involving modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/063857
Other languages
French (fr)
Other versions
WO2008144483A2 (en
Inventor
Hongwu Gao
Sandro Belvedere
Yael Webb
Donald Landry
Shixian Deng
Zhenzhuang Cheng
Jiaming Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rycarma Therapeutics Inc
Original Assignee
Armgo Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armgo Pharma Inc filed Critical Armgo Pharma Inc
Priority to TW097118419A priority Critical patent/TW200902026A/en
Priority to ARP080102126A priority patent/AR067845A1/en
Publication of WO2008144483A2 publication Critical patent/WO2008144483A2/en
Anticipated expiration legal-status Critical
Publication of WO2008144483A3 publication Critical patent/WO2008144483A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides new agents and compounds effective for treating disorders and diseases associated with RyRs, including cardiac, muscular and cognitive disorders and diseases. These agents are derivatives of benzoxazepines, benzodiazepines and benzazapines. More particularly, the invention provides compounds which include derivatives of benzoxazepine, and their enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, polymorphs, metabolites, and prodrugs thereof.
PCT/US2008/063857 2007-05-18 2008-05-16 Agents for treating disorders involving modulation of ryanodine receptors Ceased WO2008144483A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TW097118419A TW200902026A (en) 2007-05-18 2008-05-19 Agents for treating disorders involving modulation of ryanodine receptors
ARP080102126A AR067845A1 (en) 2007-05-18 2008-05-19 COMPOUNDS TO TREAT DISORDERS RELATED TO THE MODULATION OF RIANODINE RECEPTORS AND PHARMACEUTICAL COMPOSITION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93076307P 2007-05-18 2007-05-18
US60/930,763 2007-05-18

Publications (2)

Publication Number Publication Date
WO2008144483A2 WO2008144483A2 (en) 2008-11-27
WO2008144483A3 true WO2008144483A3 (en) 2012-08-16

Family

ID=40122265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063857 Ceased WO2008144483A2 (en) 2007-05-18 2008-05-16 Agents for treating disorders involving modulation of ryanodine receptors

Country Status (3)

Country Link
AR (1) AR067845A1 (en)
TW (1) TW200902026A (en)
WO (1) WO2008144483A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010056865A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
US8648066B2 (en) 2009-05-22 2014-02-11 Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
WO2010138490A1 (en) * 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
BRPI1010896A2 (en) * 2009-05-26 2019-09-24 Exelixis Inc benzoxazepines as pi3k / mtor inhibitors and methods of their use and manufacture
EA025824B1 (en) 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Fused heterocyclic compounds as ion channel modulators
ES2529119T3 (en) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Condensed heterocyclic compounds as ion channel modulators
WO2012019071A1 (en) * 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
KR20140033377A (en) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 Fused heterocyclic compounds as sodium channel modulators
AU2013201608B9 (en) * 2011-07-01 2015-07-23 Gilead Sciences, Inc. Fused benzoxazepinones as ion channel modulators
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compound as ion channel regulator
NO3175985T3 (en) * 2011-07-01 2018-04-28
AU2015224425B2 (en) * 2011-07-01 2017-02-09 Gilead Sciences, Inc. Fused benzoxazepinones as ion channel modulators
AU2013203252B2 (en) * 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
AU2014364783B2 (en) * 2013-12-19 2017-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
ES2643856B1 (en) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles for the regulation of intracellular calcium homeostasis
WO2018124001A1 (en) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmp-signal-inhibiting compound
IL302866A (en) * 2020-11-17 2023-07-01 Armgo Pharma Inc Agents for treating disorders involving ryanodine receptors
AU2022205964A1 (en) 2021-01-08 2023-08-17 Rycarma Therapeutics, Inc. Crystalline forms of a ryanodine receptor modulator and uses thereof
WO2022246114A2 (en) 2021-05-20 2022-11-24 Armgo Pharma, Inc. Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
EP4548971A1 (en) 2023-11-06 2025-05-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin 1,4-benzothiazepines and related compounds with cyclopropanol groups as multi-targeted drugs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125538A (en) * 1977-02-04 1978-11-14 Bristol-Myers Company Substituted 5-phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepines
US4592866A (en) * 1982-09-30 1986-06-03 A. H. Robins Company, Inc. Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
WO1998047876A1 (en) * 1997-04-24 1998-10-29 Akzo Nobel N.V. Heterocyclic derivatives and their use as antithrombotic agents
US6489322B1 (en) * 1997-05-05 2002-12-03 Astrazeneca Ab Amidine derivatives as inhibitors of nitric oxide synthase
WO2007024717A2 (en) * 2005-08-25 2007-03-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryr receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125538A (en) * 1977-02-04 1978-11-14 Bristol-Myers Company Substituted 5-phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepines
US4592866A (en) * 1982-09-30 1986-06-03 A. H. Robins Company, Inc. Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
WO1998047876A1 (en) * 1997-04-24 1998-10-29 Akzo Nobel N.V. Heterocyclic derivatives and their use as antithrombotic agents
US6489322B1 (en) * 1997-05-05 2002-12-03 Astrazeneca Ab Amidine derivatives as inhibitors of nitric oxide synthase
WO2007024717A2 (en) * 2005-08-25 2007-03-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryr receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISHICHI Y ET AL: "Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]p ropanoyl}-1,2,5,6-tetrahydro-4H-pyrr olo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 6, 15 March 2005 (2005-03-15), pages 1901 - 1911, XP004758992, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2005.01.022 *
PATANI G A ET AL: "BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY, US, vol. 96, no. 8, 1 January 1996 (1996-01-01), pages 3147 - 3176, XP000652176, ISSN: 0009-2665, DOI: 10.1021/CR950066Q *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
US12441691B2 (en) 2020-11-06 2025-10-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof

Also Published As

Publication number Publication date
AR067845A1 (en) 2009-10-28
TW200902026A (en) 2009-01-16
WO2008144483A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008144483A3 (en) Agents for treating disorders involving modulation of ryanodine receptors
IL202617A0 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009006567A3 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
NZ595738A (en) Benzimidazole-piperidine-cyclohexane derivatives which have activity at M1 receptor and their uses in medicine
MY147628A (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
PH12021552913A1 (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
IN2014KN02886A (en)
IL194076A (en) Benzo[d]imidazo[2,1-b]thiazol-2-ylphenyl compounds for the treatment of disease
MX2013005535A (en) 3-(aminoaryl)-pyridine compounds.
MY157495A (en) 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
DK2054418T3 (en) Dihydrothienopyrimidines as AKT protein kinase inhibitors
IL181387A0 (en) Fused tricyclic derivatives for the treatment of psychotic disorders
MX2009004096A (en) Talarazole metabolites.
MX2011013016A (en) Aminopyrrolidinone derivatives and uses thereof.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
MX2010001304A (en) Therapeutic compounds.
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
MX2007011280A (en) Dipyrazoles as central nervous system agents.
WO2007097871A3 (en) Piperazine derivatives
TW200724143A (en) Novel compounds for the treatment of inflammatory diseases
TW200633997A (en) Substituted heterocyclic compounds and thrombopoietin receptor activators
IL194390A0 (en) Heterocyclic gaba alpha subtype selective receptor modulators
ZA200701139B (en) Fused tricyclic derivatives for the treatment of psychotic disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08755663

Country of ref document: EP

Kind code of ref document: A2